Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Average: 2022-2025

Historic Equity Average for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $3.4 million.

  • bioAffinity Technologies' Equity Average rose 3.23% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 3.23%. This contributed to the annual value of $3.7 million for FY2024, which is 53.09% down from last year.
  • Per bioAffinity Technologies' latest filing, its Equity Average stood at $3.4 million for Q3 2025, which was up 1,071.16% from -$348,352 recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Equity Average peaked at $11.8 million during Q4 2022, and registered a low of -$348,352 during Q2 2025.
  • Its 3-year average for Equity Average is $4.8 million, with a median of $4.3 million in 2024.
  • Data for bioAffinity Technologies' Equity Average shows a peak YoY increase of 3.23% (in 2025) and a maximum YoY decrease of 108.02% (in 2025) over the last 5 years.
  • bioAffinity Technologies' Equity Average (Quarterly) stood at $11.8 million in 2022, then crashed by 49.88% to $5.9 million in 2023, then slumped by 51.70% to $2.9 million in 2024, then rose by 3.23% to $3.4 million in 2025.
  • Its Equity Average was $3.4 million in Q3 2025, compared to -$348,352 in Q2 2025 and $2.0 million in Q1 2025.